What Are Neurodevelopmental Outcomes After Neonatal HSV?

When a baby is diagnosed with a herpes simplex virus (HSV) infection, one of the most pressing questions for parents is whether the infection will cause long-term neurodevelopmental impairment. The direct answer is that the long-term outlook depends heavily on when the infection was acquired, how far the virus spread, and how quickly antiviral treatment began. While modern treatments have significantly improved outcomes, infants who had the virus in their brain or throughout their body, or who acquired the infection in the womb, still face a substantial risk of lasting developmental challenges.

It is important to first distinguish between congenital HSV (acquired in the womb) and neonatal HSV (acquired during or shortly after birth), as doctors evaluate them differently.

Congenital (In-Utero) HSV

True congenital HSV is very rare, making up only about 5% of all newborn HSV cases ^{[1] [2]}. Because the virus affects the fetus during crucial stages of development in the womb, it often presents with a specific triad of symptoms at birth: skin lesions, microcephaly (a smaller than normal head size due to abnormal brain development), and eye issues such as chorioretinitis (inflammation of the retina) ^[3].

Infants with true congenital HSV face high risks of severe long-term complications, including developmental delays, seizures, and abnormal brain calcifications ^{[3] [4]}. Because this form of the infection is so rare, precise population-wide survival and impairment rates are difficult to establish, and a baby’s individual prognosis will depend heavily on their specific brain imaging, eye exams, and neurological evaluations.

Neonatal HSV Outcomes Based on Infection Type

For the 95% of cases where HSV is acquired during or just after birth, doctors classify the infection into three categories. These group-level statistics provide a framework for understanding risk, but they do not predict the exact future of an individual child.

Skin, Eyes, and Mouth (SEM) Disease

When the infection is limited to the skin, eyes, and mouth, the long-term neurologic outlook is generally very positive ^[5]. Because there is no clinical evidence that the virus has reached the brain or internal organs, the risk of neurodevelopmental impairment is lowest in this group. However, it is not completely risk-free. In one large UK/Ireland surveillance study, about 11.8% of infants with SEM disease who were followed up at 24 months showed some level of neurodevelopmental impairment ^[6]. Prompt treatment is critical, as untreated SEM disease can progress to more severe forms ^{[5] [7]}.

Central Nervous System (CNS) Disease

If the virus infects the brain (causing encephalitis, or brain inflammation), the risk of long-term impairment is much higher. Despite aggressive antiviral treatment, many infants with CNS disease experience persistent neurological challenges. In the UK/Ireland study, among survivors assessed at 24 months, 45% of infants with CNS disease had some form of neurodevelopmental impairment ^[6]. Another large study spanning from 1980 to 2016 in Seattle found that only 55% of infants who survived CNS disease were without obvious neurological abnormalities at two years of age ^[8].

Disseminated Disease

Disseminated disease means the virus has spread throughout the body, affecting multiple internal organs (like the liver and lungs) and sometimes the brain. This is the most dangerous form of neonatal HSV and carries the highest risk of early mortality. In the UK/Ireland surveillance study, 65.8% of infants with disseminated disease did not survive ^[6]. In the Seattle cohort, mortality was 40.9% among infants treated with modern high-dose acyclovir ^[8]. For the infants who do survive disseminated disease, the risk of long-term neurodevelopmental impairment is also significant, affecting roughly 25% of survivors assessed at 24 months in the UK/Ireland cohort ^[6].

What Does “Neurodevelopmental Impairment” Mean?

When doctors discuss “neurodevelopmental impairment” or adverse neurological outcomes, they are referring to a broad spectrum of challenges. This does not always mean severe “brain damage.” Impairments can range from mild delays in language and social skills to more severe global developmental delays, cerebral palsy, movement disorders, hearing loss, vision loss, or the development of seizures ^{[9] [10] [11]}.

The Impact of Treatment and Ongoing Care

Early and aggressive treatment with high-dose intravenous (IV) acyclovir has significantly reduced the overall mortality rate for neonatal HSV ^[8]. While antiviral drugs cannot reliably undo brain injury that has already occurred, they stop viral replication and limit ongoing damage, which is why delayed treatment is linked to poorer long-term outcomes ^{[12] [6]}.

For many infants, particularly those with CNS involvement, doctors may recommend a six-month course of oral suppressive acyclovir after the initial IV treatment. This regimen has been associated with improved long-term neurodevelopmental outcomes for CNS disease and helps reduce the recurrence of skin outbreaks ^{[5] [13]}. However, this medication requires careful monitoring of blood counts and kidney function.

Because developmental, learning, hearing, and vision problems may become apparent as a child grows past age two, continuous monitoring is essential. Based on your baby’s specific diagnosis, your pediatrician can coordinate care with specialists like neurologists, ophthalmologists, and audiologists, and connect you with early intervention therapies (physical, occupational, and speech) to support your child’s growth and help them reach their full potential.